公司的客户包括下游行业(如汽车、新能源及家电)的制造商及下游制造商的供应链解决方案提供商。就 公司的大健康板块而言，客户主要包括医疗及药品制造商，彼等使用公司的产品作为生产补充剂和药品 等下游产品的原材料。 根据弗若斯特沙利文的资料，按2024年中国骨明胶行业产量计，公司是中国市场产量位居第二、中国内 资品牌产量位居第一的骨明胶生产企业；按2024年中国空心胶囊行业相关产量计，公司是中国内资品牌 产量第二大的空心胶囊生产企业。 财务方面，于2022财年、2023财年、2024财年以及2025财年首十个月，公司实现收入分别约为134.06亿 元(人民币，下同)、174.39亿元、191.88亿元以及174.44亿元；同期，录得年内利润分别为7.24亿元、5.4 亿元、7.21亿元以及7.21亿元。 公司将收取的所得款项净额将约为10.58亿港元，假设发售价为每股H股38.00港元(即指示性发售价范围 的中位数)。约50.0%将分配至扩大公司位于泰国的新生产基地的产能；约35.0%将分配至扩大公司位于 中国的新生产基地产能；约10.0%将分配至公司在香港的投资，包括设立地区总部及生产基地升级；约 5.0%所得款项 ...

招股书显示，国恩科技创立于2000年，是一家专注于化工新材料及明胶、胶原蛋白上下游产品的中国供 应商。公司服务于化工行业及大健康行业，主要从事工业及商业用途产品的研发、生产及销售。公司于 2011年完成股份改制，公司A股(国恩股份，002768.SZ)于2015年6月在深交所上市。 公司的客户包括下游行业(如汽车、新能源及家电)的制造商及下游制造商的供应链解决方案提供商。就 公司的大健康板块而言，客户主要包括医疗及药品制造商，彼等使用公司的产品作为生产补充剂和药品 等下游产品的原材料。 根据弗若斯特沙利文的资料，按2024年中国骨明胶行业产量计，公司是中国市场产量位居第二、中国内 资品牌产量位居第一的骨明胶生产企业；按2024年中国空心胶囊行业相关产量计，公司是中国内资品牌 产量第二大的空心胶囊生产企业。 财务方面，于2022财年、2023财年、2024财年以及2025财年首十个月，公司实现收入分别约为134.06亿 元(人民币，下同)、174.39亿元、191.88亿元以及174.44亿元；同期，录得年内利润分别为7.24亿元、5.4 亿元、7.21亿元以及7.21亿元。 公司将收取的所得款项净额将约为10 ...

国恩科技(02768.HK)发布公告，公司拟全球发售3000万股H股，中国香港发售股份300万股，国际发售股份2700万股(以上可予重新分配)；2026年1月27日 至1月30日招股，预期定价日为2月2日；发售价每股发售股份34.00-42.00港元，H股的每手买卖单位将为200股，招商证券国际为独家保荐人；预期H股将 于2026年2月4日开始于联交所买卖。 公司已订立基石投资协议，据此，基石投资者已同意遵照若干条件，按发售价认购或促使其指定实体认购可购入的有关数目的发售股份，总金额为约3.2 亿港元。假设发售价为42.00港元(即招股章程所述最高发售价)，基石投资者将认购的发售股份总数将为760.2万股发售股份。 基石投资者包括利冠投资有限公司("利冠")、SLD International Enterprises Limited("SLD International")、丞安国际有限公司("丞安国际")、申万宏源证券、 First Seafront Fund Series SPC、新嘉财富证券有限公司("新嘉财富")、Luminous Horizon Limited("Luminous Horizon") ...

Core Viewpoint - Qingdao Guoen Technology Co., Ltd. is preparing for its listing on the Hong Kong Stock Exchange, focusing on new chemical materials and gelatin, with a strong emphasis on both the chemical and health industries [1]. Group 1: Company Overview - Guoen Technology specializes in the research, production, and sales of products for the chemical and health industries, serving clients in sectors such as automotive, renewable energy, and healthcare [3]. - The company is recognized as the second-largest producer of organic polymer modified materials and organic polymer composite materials in China, holding a market share of 2.5% as of 2024 [4]. Group 2: Product and Market Position - In the chemical sector, Guoen's product range includes upstream green petrochemical materials and midstream organic polymer modified materials, catering to diverse applications in electronics, automotive, and energy storage [4]. - In the health sector, the company focuses on the natural collagen industry, with its subsidiary Dongbao Bio leveraging a vertically integrated strategy to cover the entire value chain from collagen to end products [5]. Group 3: Financial Performance - The company's revenue for the fiscal years 2022, 2023, 2024, and the first ten months of 2025 were approximately RMB 134.06 billion, RMB 174.39 billion, RMB 191.88 billion, and RMB 174.44 billion, respectively [6]. - The net profit for the same periods was RMB 7.24 billion, RMB 5.4 billion, RMB 7.21 billion, and RMB 7.21 billion [6].

Group 1: Company Overview - Qingdao Guoen Technology Co., Ltd. (002768.SZ) is focused on new chemical materials and gelatin, collagen upstream and downstream products, and has passed the listing hearing on the Hong Kong Stock Exchange [1] - The company serves the chemical and health industries, primarily engaged in the R&D, production, and sales of products for industrial and commercial use [3] Group 2: Industry Position - In the chemical industry, Guoen Technology is the second-largest company in China for organic polymer modified materials and organic polymer composite materials, with a market share of 2.5% as of 2024 [4] - The company is also the largest producer of polystyrene in China by production capacity as of 2024 [4] Group 3: Product and Market Focus - Guoen Technology focuses on the natural collagen industry, with a vertical integration strategy that covers collagen peptide derivatives to end products [5] - The company is the second-largest producer of bone gelatin in China and the second-largest domestic brand in the hollow capsule production industry as of 2024 [6] Group 4: Market Growth - The market size for organic polymer modified materials and organic polymer composite materials is projected to grow from RMB 303.8 billion in 2020 to RMB 544.8 billion in 2024, with a compound annual growth rate (CAGR) of 15.7% [6] - The market is expected to continue growing at a CAGR of 14.1% from 2025 to 2029, reaching RMB 1,037.5 billion by 2029 [6] Group 5: Financial Performance - Guoen Technology's revenues for the fiscal years 2022, 2023, 2024, and the first ten months of 2025 were approximately RMB 13.41 billion, RMB 17.44 billion, RMB 19.19 billion, and RMB 17.44 billion respectively [6][7] - The company reported net profits of RMB 724 million, RMB 540 million, RMB 721 million, and RMB 721 million for the same periods [6][8]

Group 1 - Qingdao Gon Technology Co., Ltd. has received approval from the China Securities Regulatory Commission for overseas issuance of up to 54.05 million shares, which will be listed on the Hong Kong Stock Exchange [1] - The company was established in 2000 and focuses on technological innovation, aiming for long-term scale efficiency in the large chemical and health industries [1] - As of 2024, Qingdao Gon is the second-largest organic polymer material modification producer in China and the largest producer of polystyrene based on production capacity [1] Group 2 - In the health industry, Qingdao Gon ranks second in bone gelatin production volume in China and is the leading domestic brand in this sector as of 2024 [2] - The company is also the second-largest domestic brand producer of hollow capsules in China based on production volume in 2024 [2]